Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Operating Leases (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Operating Leases readings, the most recent being $9.1 million for Q1 2026.

  • On a quarterly basis, Operating Leases fell 66.02% to $9.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $9.1 million, a 66.02% decrease, with the full-year FY2025 number at $9.3 million, down 68.75% from a year prior.
  • Operating Leases hit $9.1 million in Q1 2026 for Atara Biotherapeutics, down from $9.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $64.0 million in Q2 2022 to a low of $9.1 million in Q1 2026.
  • Median Operating Leases over the past 5 years was $38.7 million (2024), compared with a mean of $36.7 million.
  • Biggest five-year swings in Operating Leases: soared 214.66% in 2023 and later tumbled 68.75% in 2025.
  • Atara Biotherapeutics' Operating Leases stood at $58.1 million in 2022, then fell by 21.31% to $45.7 million in 2023, then crashed by 34.53% to $29.9 million in 2024, then tumbled by 68.75% to $9.3 million in 2025, then fell by 2.9% to $9.1 million in 2026.
  • The last three reported values for Operating Leases were $9.1 million (Q1 2026), $9.3 million (Q4 2025), and $15.0 million (Q3 2025) per Business Quant data.